EyePoint Announces Positive 6-Month Data From Duravyu Trial For Diabetic Macular Edema
(RTTNews) - EyePoint Pharmaceuticals, Inc. (EYPT), Wednesday announced positive six-month results from the ongoing Phase 2 VERONA clinical trial, evaluating Duravyu for the treatment of diabetic ...
CyberArk and SentinelOne team on endpoint and identity security
CyberArk (CYBR) announced a new integration with SentinelOne (S) AI-powered cybersecurity platform, SentinelOne Singularity, to protect against ...
RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate Cancer
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced ...
The American Journal of Managed Care1d
OIG Report Seeks Better Oversight, Records for FDA’s Accelerated Approvals
Amid the uproar over the firing of 18 inspectors general, a report offering a coda to the aducanumab approval episode has ...
News Medical6d
Cancer-fighting virus T-VEC helps shrink tough-to-treat skin tumors
Talimogene laherparepvec (T-VEC) demonstrates efficacy in cutaneous BCC, enhancing resectability and altering immune cell ...
News Medical6d
The key to healthy aging? Exercise might be the answer
Older adults who regularly exercise have a better quality of life, even if they have AD or suffer from depression. Increased ...
TMCnet6d
AV-Comparatives Releases 2024 Summary Report: Celebrating Excellence in Cybersecurity
The 2024 evaluation encompassed the following security solutions: In 2024, AV-Comparatives conducted a series of ...